Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.
In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.